A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication

Abstract

Objectives Oxygen 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a significant prognostic biomarker in astrocytomas, especially for temozolomide (TMZ) chemotherapy. This study aimed to preoperatively predict MGMT methylation status based on magnetic resonance imaging (MRI) radiomics and validate its value for evaluation of TMZ chemotherapy effect. Methods We retrospectively reviewed a cohort of 105 patients with grade II-IV astrocytomas. Radiomic features were extracted from the tumour and peritumoral oedema habitats on contrast-enhanced T1-weighted images, T2-weighted fluid-attenuated inversion recovery images and apparent diffusion coefficient (ADC) maps. The following radiomics analysis was structured in three phases: feature reduction, signature construction and discrimination statistics. A fusion radiomics signature was finally developed using logistic regression modelling. Predictive performance was compared between the radiomics signature, previously reported clinical factors and ADC parameters. Validation was additionally performed on a time-independent cohort (n = 31). The prognostic value of the signature on overall survival for TMZ chemotherapy was explored using Kaplan Meier estimation. Results The fusion radiomics signature exhibited supreme power for predicting MGMT promoter methylation, with area under the curve values of 0.925 in the training cohort and 0.902 in the validation cohort. Performance of the radiomics signature surpassed that of clinical factors and ADC parameters. Moreover, the radiomics approach successfully divided patients into highrisk and low-risk groups for overall survival after TMZ chemotherapy (p = 0.03). Conclusions The proposed radiomics signature accurately predicted MGMT promoter methylation in patients with astrocytomas, and achieved survival stratification for TMZ chemotherapy, thus providing a preoperative basis for individualised treatment planning. Key Points • Radiomics using magnetic resonance imaging can preoperatively perform satisfactory prediction of MGMT methylation in grade II-IV astrocytomas.• Habitat-based radiomics can improve efficacy in predicting MGMT methylation status.• Multi-sequence radiomics signature has the power to evaluate TMZ chemotherapy effect.

A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma

“…To evaluate the sample size for the validation group, we performed a power analysis based on the LNM rates of the training dataset and the validation dataset. Normally, a power value greater than 0.8 suggests a sufficient sample size 57, 58. Our estimated power value was 0.85 for the current study.…”

Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation

“…Given the relative abundance of high quality MRI data which accumulates over time during standard of care for glioma patients (85–87) radiomics offers a potentially efficient and non-invasive method of tumoral evaluation (37, 88, 89). Indeed, recent efforts have generated radiomic signatures to predict the majority of information sought by classical histopathological and modern molecular assessments including: isocitrate dehydrogenase mutations (79, 90–92), 1p/19q codeletion loss of heterozygosity (24, 92, 93), O 6 -methylguanine-DNA methyltransferase promoter methylation (45, 94) and ATRX mutations (95). This has culminated in recent findings demonstrating a conserved radiomic signature can predict CD8+ T-cell infiltration and response to immunotherapy (96).…”

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma

“…Similarly, in an attempt to exploit the full potential of medical imaging, Xi et al [9] also developed a predictive model in which different sets of radiomics features were investigated. Wei et al [10] proposed the fusion radiomics signature that can identify MGMT methylation status in patients with World Health Organization grade II-IV astrocytoma, providing an effective preoperative diagnosis for individualized treatment.…”